Becton, Dickinson and Company (NYSE: BDXA) Stock Competitors & Peer Comparison
See BDXA's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BDXA and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.39% |
| BDX | $156.36 | +2.22% | 56.6B | 11.62 | $13.45 | +2.39% |
| MDLN | $38.75 | +2.98% | 32.8B | 45.06 | $0.86 | N/A |
| WST | $328.20 | -7.67% | 23.2B | 41.19 | $7.97 | +0.26% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| COO | $70.31 | +0.11% | 13.7B | 15.42 | $4.56 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.39% |
| BAX | $22.40 | +3.37% | 11.6B | 10.77 | $2.08 | +0.89% |
| ATR | $132.36 | +2.61% | 8.4B | 23.13 | $5.72 | +1.43% |
| AVTR | $11.44 | +0.79% | 7.8B | 13.46 | $0.85 | N/A |
Stock Comparison
Becton, Dickinson and Company (NYSE: BDX)
BDXA vs BDX Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, BDX has a market cap of 56.6B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while BDX trades at $156.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas BDX's P/E ratio is 11.62. In terms of profitability, BDXA's ROE is +0.05%, compared to BDX's ROE of +0.05%. Regarding short-term risk, BDXA is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check BDX's competition here
Medline Inc. (NASDAQ: MDLN)
BDXA vs MDLN Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, MDLN has a market cap of 32.8B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while MDLN trades at $38.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas MDLN's P/E ratio is 45.06. In terms of profitability, BDXA's ROE is +0.05%, compared to MDLN's ROE of +0.07%. Regarding short-term risk, BDXA is more volatile compared to MDLN. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
BDXA vs WST Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, WST has a market cap of 23.2B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while WST trades at $328.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas WST's P/E ratio is 41.19. In terms of profitability, BDXA's ROE is +0.05%, compared to WST's ROE of +0.19%. Regarding short-term risk, BDXA is less volatile compared to WST. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
BDXA vs HOLX Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas HOLX's P/E ratio is 31.54. In terms of profitability, BDXA's ROE is +0.05%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, BDXA is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check HOLX's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
BDXA vs COO Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, COO has a market cap of 13.7B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while COO trades at $70.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas COO's P/E ratio is 15.42. In terms of profitability, BDXA's ROE is +0.05%, compared to COO's ROE of +0.03%. Regarding short-term risk, BDXA is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check COO's competition here
Becton, Dickinson and Company (NYSE: BDXB)
BDXA vs BDXB Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas BDXB's P/E ratio is 7.60. In terms of profitability, BDXA's ROE is +0.05%, compared to BDXB's ROE of +0.05%. Regarding short-term risk, BDXA is more volatile compared to BDXB. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
BDXA vs BAX Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, BAX has a market cap of 11.6B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while BAX trades at $22.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas BAX's P/E ratio is 10.77. In terms of profitability, BDXA's ROE is +0.05%, compared to BAX's ROE of -0.16%. Regarding short-term risk, BDXA is more volatile compared to BAX. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check BAX's competition here
AptarGroup, Inc. (NYSE: ATR)
BDXA vs ATR Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, ATR has a market cap of 8.4B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while ATR trades at $132.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas ATR's P/E ratio is 23.13. In terms of profitability, BDXA's ROE is +0.05%, compared to ATR's ROE of +0.14%. Regarding short-term risk, BDXA is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check ATR's competition here
Avantor, Inc. (NYSE: AVTR)
BDXA vs AVTR Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, AVTR has a market cap of 7.8B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while AVTR trades at $11.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas AVTR's P/E ratio is 13.46. In terms of profitability, BDXA's ROE is +0.05%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, BDXA is more volatile compared to AVTR. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check AVTR's competition here
Repligen Corporation (NASDAQ: RGEN)
BDXA vs RGEN Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, RGEN has a market cap of 7.4B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while RGEN trades at $131.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas RGEN's P/E ratio is 73.31. In terms of profitability, BDXA's ROE is +0.05%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, BDXA is more volatile compared to RGEN. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check RGEN's competition here
Teleflex Incorporated (NYSE: TFX)
BDXA vs TFX Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, TFX has a market cap of 5.8B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while TFX trades at $132.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas TFX's P/E ratio is 12.32. In terms of profitability, BDXA's ROE is +0.05%, compared to TFX's ROE of -0.28%. Regarding short-term risk, BDXA is more volatile compared to TFX. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check TFX's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
BDXA vs BLCO Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, BLCO has a market cap of 5.8B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while BLCO trades at $16.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas BLCO's P/E ratio is 24.88. In terms of profitability, BDXA's ROE is +0.05%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, BDXA is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check BLCO's competition here
Stevanato Group S.p.A. (NYSE: STVN)
BDXA vs STVN Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, STVN has a market cap of 5.4B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while STVN trades at $19.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas STVN's P/E ratio is 31.81. In terms of profitability, BDXA's ROE is +0.05%, compared to STVN's ROE of +0.10%. Regarding short-term risk, BDXA is more volatile compared to STVN. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check STVN's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
BDXA vs MMSI Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, MMSI has a market cap of 4.4B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while MMSI trades at $74.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas MMSI's P/E ratio is 19.01. In terms of profitability, BDXA's ROE is +0.05%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, BDXA is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
BDXA vs ICUI Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, ICUI has a market cap of 3.9B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while ICUI trades at $157.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas ICUI's P/E ratio is 19.66. In terms of profitability, BDXA's ROE is +0.05%, compared to ICUI's ROE of +0.02%. Regarding short-term risk, BDXA is more volatile compared to ICUI. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check ICUI's competition here
Haemonetics Corporation (NYSE: HAE)
BDXA vs HAE Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, HAE has a market cap of 3.6B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while HAE trades at $78.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas HAE's P/E ratio is 15.86. In terms of profitability, BDXA's ROE is +0.05%, compared to HAE's ROE of +0.11%. Regarding short-term risk, BDXA is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check HAE's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
BDXA vs XRAY Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, XRAY has a market cap of 2.6B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while XRAY trades at $12.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas XRAY's P/E ratio is 9.04. In terms of profitability, BDXA's ROE is +0.05%, compared to XRAY's ROE of -0.41%. Regarding short-term risk, BDXA is more volatile compared to XRAY. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check XRAY's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
BDXA vs LMAT Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, LMAT has a market cap of 2.2B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while LMAT trades at $95.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas LMAT's P/E ratio is 37.05. In terms of profitability, BDXA's ROE is +0.05%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, BDXA is more volatile compared to LMAT. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check LMAT's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
BDXA vs PLSE Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, PLSE has a market cap of 2.1B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while PLSE trades at $30.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas PLSE's P/E ratio is -27.48. In terms of profitability, BDXA's ROE is +0.05%, compared to PLSE's ROE of -0.87%. Regarding short-term risk, BDXA is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
BDXA vs ATRC Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, ATRC has a market cap of 1.8B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while ATRC trades at $35.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas ATRC's P/E ratio is 1088.20. In terms of profitability, BDXA's ROE is +0.05%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, BDXA is less volatile compared to ATRC. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check ATRC's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
BDXA vs BLFS Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, BLFS has a market cap of 1.5B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while BLFS trades at $29.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas BLFS's P/E ratio is -141.85. In terms of profitability, BDXA's ROE is +0.05%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, BDXA is more volatile compared to BLFS. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check BLFS's competition here
Azenta, Inc. (NASDAQ: AZTA)
BDXA vs AZTA Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, AZTA has a market cap of 1.3B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while AZTA trades at $27.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas AZTA's P/E ratio is 60.82. In terms of profitability, BDXA's ROE is +0.05%, compared to AZTA's ROE of -0.11%. Regarding short-term risk, BDXA is more volatile compared to AZTA. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
BDXA vs KMTS Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, KMTS has a market cap of 1.2B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while KMTS trades at $21.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas KMTS's P/E ratio is -8.92. In terms of profitability, BDXA's ROE is +0.05%, compared to KMTS's ROE of -0.59%. Regarding short-term risk, BDXA is more volatile compared to KMTS. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
BDXA vs STAA Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, STAA has a market cap of 1.2B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while STAA trades at $23.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas STAA's P/E ratio is 41.02. In terms of profitability, BDXA's ROE is +0.05%, compared to STAA's ROE of -0.06%. Regarding short-term risk, BDXA is more volatile compared to STAA. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check STAA's competition here
QuidelOrtho Corporation (NASDAQ: QDEL)
BDXA vs QDEL Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, QDEL has a market cap of 1.1B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while QDEL trades at $16.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas QDEL's P/E ratio is 11.98. In terms of profitability, BDXA's ROE is +0.05%, compared to QDEL's ROE of -0.56%. Regarding short-term risk, BDXA is less volatile compared to QDEL. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check QDEL's competition here
Atrion Corporation (NASDAQ: ATRI)
BDXA vs ATRI Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas ATRI's P/E ratio is 64.50. In terms of profitability, BDXA's ROE is +0.05%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, BDXA is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
BDXA vs ANGO Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, ANGO has a market cap of 561.7M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while ANGO trades at $13.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas ANGO's P/E ratio is -34.85. In terms of profitability, BDXA's ROE is +0.05%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, BDXA is more volatile compared to ANGO. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check ANGO's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
BDXA vs NNNN Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, NNNN has a market cap of 441.5M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while NNNN trades at $9.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas NNNN's P/E ratio is 145.38. In terms of profitability, BDXA's ROE is +0.05%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, BDXA is more volatile compared to NNNN. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check NNNN's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
BDXA vs OSUR Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, OSUR has a market cap of 273.3M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while OSUR trades at $3.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas OSUR's P/E ratio is -4.78. In terms of profitability, BDXA's ROE is +0.05%, compared to OSUR's ROE of -0.21%. Regarding short-term risk, BDXA is more volatile compared to OSUR. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check OSUR's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
BDXA vs SMTI Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, SMTI has a market cap of 234.2M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while SMTI trades at $25.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas SMTI's P/E ratio is -426.00. In terms of profitability, BDXA's ROE is +0.05%, compared to SMTI's ROE of -2.46%. Regarding short-term risk, BDXA is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check SMTI's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
BDXA vs UTMD Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, UTMD has a market cap of 213.8M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while UTMD trades at $67.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas UTMD's P/E ratio is 19.86. In terms of profitability, BDXA's ROE is +0.05%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, BDXA is less volatile compared to UTMD. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check UTMD's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
BDXA vs INFU Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, INFU has a market cap of 183.9M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while INFU trades at $9.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas INFU's P/E ratio is 23.97. In terms of profitability, BDXA's ROE is +0.05%, compared to INFU's ROE of +0.14%. Regarding short-term risk, BDXA is more volatile compared to INFU. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check INFU's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
BDXA vs KRMD Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, KRMD has a market cap of 175.9M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while KRMD trades at $3.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas KRMD's P/E ratio is -95.75. In terms of profitability, BDXA's ROE is +0.05%, compared to KRMD's ROE of -0.14%. Regarding short-term risk, BDXA is more volatile compared to KRMD. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check KRMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
BDXA vs PDEX Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, PDEX has a market cap of 175.4M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while PDEX trades at $54.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas PDEX's P/E ratio is 19.34. In terms of profitability, BDXA's ROE is +0.05%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, BDXA is more volatile compared to PDEX. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check PDEX's competition here
Microbot Medical Inc. (NASDAQ: MBOT)
BDXA vs MBOT Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, MBOT has a market cap of 77.9M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while MBOT trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas MBOT's P/E ratio is -6.58. In terms of profitability, BDXA's ROE is +0.05%, compared to MBOT's ROE of -0.22%. Regarding short-term risk, BDXA is more volatile compared to MBOT. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check MBOT's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
BDXA vs AKYA Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas AKYA's P/E ratio is -1.34. In terms of profitability, BDXA's ROE is +0.05%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, BDXA is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check AKYA's competition here
SkyAI, Inc. (NASDAQ: STSS)
BDXA vs STSS Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, STSS has a market cap of 58.4M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while STSS trades at $1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas STSS's P/E ratio is -0.02. In terms of profitability, BDXA's ROE is +0.05%, compared to STSS's ROE of -1.66%. Regarding short-term risk, BDXA is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check STSS's competition here
Daxor Corporation (NASDAQ: DXR)
BDXA vs DXR Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, DXR has a market cap of 52.7M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while DXR trades at $10.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas DXR's P/E ratio is 27.33. In terms of profitability, BDXA's ROE is +0.05%, compared to DXR's ROE of +0.22%. Regarding short-term risk, BDXA is more volatile compared to DXR. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check DXR's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
BDXA vs OMIC Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas OMIC's P/E ratio is -0.58. In terms of profitability, BDXA's ROE is +0.05%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, BDXA is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
BDXA vs IGAP Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas IGAP's P/E ratio is -10.52. In terms of profitability, BDXA's ROE is +0.05%, compared to IGAP's ROE of -0.86%. Regarding short-term risk, BDXA is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check IGAP's competition here
Nephros, Inc. (NASDAQ: NEPH)
BDXA vs NEPH Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, NEPH has a market cap of 38.6M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while NEPH trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas NEPH's P/E ratio is 50.86. In terms of profitability, BDXA's ROE is +0.05%, compared to NEPH's ROE of +0.08%. Regarding short-term risk, BDXA is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check NEPH's competition here
Milestone Scientific Inc. (AMEX: MLSS)
BDXA vs MLSS Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, MLSS has a market cap of 34.5M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while MLSS trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas MLSS's P/E ratio is -6.50. In terms of profitability, BDXA's ROE is +0.05%, compared to MLSS's ROE of -1.66%. Regarding short-term risk, BDXA is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check MLSS's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
BDXA vs POCI Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, POCI has a market cap of 33.8M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while POCI trades at $4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas POCI's P/E ratio is -6.07. In terms of profitability, BDXA's ROE is +0.05%, compared to POCI's ROE of -0.37%. Regarding short-term risk, BDXA is more volatile compared to POCI. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check POCI's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
BDXA vs SDC Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas SDC's P/E ratio is -0.03. In terms of profitability, BDXA's ROE is +0.05%, compared to SDC's ROE of -1.96%. Regarding short-term risk, BDXA is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check SDC's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
BDXA vs HBIO Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, HBIO has a market cap of 27.3M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while HBIO trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas HBIO's P/E ratio is -16.81. In terms of profitability, BDXA's ROE is +0.05%, compared to HBIO's ROE of -0.73%. Regarding short-term risk, BDXA is more volatile compared to HBIO. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check HBIO's competition here
Invacare Corporation (NYSE: IVC)
BDXA vs IVC Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas IVC's P/E ratio is -0.79. In terms of profitability, BDXA's ROE is +0.05%, compared to IVC's ROE of -0.46%. Regarding short-term risk, BDXA is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
BDXA vs RVP Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, RVP has a market cap of 20.4M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while RVP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas RVP's P/E ratio is -2.06. In terms of profitability, BDXA's ROE is +0.05%, compared to RVP's ROE of -0.08%. Regarding short-term risk, BDXA is more volatile compared to RVP. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check RVP's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
BDXA vs ZJYL Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, ZJYL has a market cap of 16M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while ZJYL trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas ZJYL's P/E ratio is 12.75. In terms of profitability, BDXA's ROE is +0.05%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, BDXA is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check ZJYL's competition here
Femasys Inc. (NASDAQ: FEMY)
BDXA vs FEMY Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, FEMY has a market cap of 11.2M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while FEMY trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas FEMY's P/E ratio is -10.25. In terms of profitability, BDXA's ROE is +0.05%, compared to FEMY's ROE of -2.58%. Regarding short-term risk, BDXA is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check FEMY's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
BDXA vs RGNT Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, RGNT has a market cap of 7.8M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while RGNT trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas RGNT's P/E ratio is -0.08. In terms of profitability, BDXA's ROE is +0.05%, compared to RGNT's ROE of N/A. Regarding short-term risk, BDXA is less volatile compared to RGNT. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check RGNT's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
BDXA vs NSTG Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas NSTG's P/E ratio is -0.03. In terms of profitability, BDXA's ROE is +0.05%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, BDXA is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check NSTG's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
BDXA vs NXGL Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, NXGL has a market cap of 4M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while NXGL trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas NXGL's P/E ratio is -1.13. In terms of profitability, BDXA's ROE is +0.05%, compared to NXGL's ROE of -0.70%. Regarding short-term risk, BDXA is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check NXGL's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
BDXA vs POAI Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas POAI's P/E ratio is -0.03. In terms of profitability, BDXA's ROE is +0.05%, compared to POAI's ROE of -107.05%. Regarding short-term risk, BDXA is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check POAI's competition here
Lucyd, Inc (NASDAQ: LUCY)
BDXA vs LUCY Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, LUCY has a market cap of 2.6M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while LUCY trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas LUCY's P/E ratio is -0.39. In terms of profitability, BDXA's ROE is +0.05%, compared to LUCY's ROE of -0.83%. Regarding short-term risk, BDXA is more volatile compared to LUCY. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check LUCY's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
BDXA vs MHUA Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas MHUA's P/E ratio is 0.25. In terms of profitability, BDXA's ROE is +0.05%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, BDXA is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check MHUA's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
BDXA vs NXGLW Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, NXGLW has a market cap of 1.8M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while NXGLW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas NXGLW's P/E ratio is -0.06. In terms of profitability, BDXA's ROE is +0.05%, compared to NXGLW's ROE of -0.70%. Regarding short-term risk, BDXA is more volatile compared to NXGLW. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check NXGLW's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
BDXA vs GMVD Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas GMVD's P/E ratio is -0.01. In terms of profitability, BDXA's ROE is +0.05%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, BDXA is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
BDXA vs GMVDW Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas GMVDW's P/E ratio is N/A. In terms of profitability, BDXA's ROE is +0.05%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, BDXA is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
BDXA vs AVGR Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas AVGR's P/E ratio is -0.05. In terms of profitability, BDXA's ROE is +0.05%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, BDXA is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check AVGR's competition here
Lucyd, Inc (NASDAQ: LUCYW)
BDXA vs LUCYW Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas LUCYW's P/E ratio is -0.00. In terms of profitability, BDXA's ROE is +0.05%, compared to LUCYW's ROE of -0.83%. Regarding short-term risk, BDXA is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check LUCYW's competition here
GlucoTrack, Inc. (NASDAQ: GCTK)
BDXA vs GCTK Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, GCTK has a market cap of 165.2K. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while GCTK trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas GCTK's P/E ratio is -0.01. In terms of profitability, BDXA's ROE is +0.05%, compared to GCTK's ROE of -5.82%. Regarding short-term risk, BDXA is less volatile compared to GCTK. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check GCTK's competition here
Invuity, Inc. (NASDAQ: IVTY)
BDXA vs IVTY Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, IVTY has a market cap of 0. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas IVTY's P/E ratio is -3.80. In terms of profitability, BDXA's ROE is +0.05%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, BDXA is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check IVTY's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
BDXA vs ATRS Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, ATRS has a market cap of 0. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas ATRS's P/E ratio is 14.95. In terms of profitability, BDXA's ROE is +0.05%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, BDXA is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check ATRS's competition here
Apria, Inc. (NASDAQ: APR)
BDXA vs APR Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, APR has a market cap of 0. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas APR's P/E ratio is 22.59. In terms of profitability, BDXA's ROE is +0.05%, compared to APR's ROE of +9.81%. Regarding short-term risk, BDXA is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check APR's competition here
IntriCon Corporation (NASDAQ: IIN)
BDXA vs IIN Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, IIN has a market cap of 0. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas IIN's P/E ratio is 226.45. In terms of profitability, BDXA's ROE is +0.05%, compared to IIN's ROE of -0.00%. Regarding short-term risk, BDXA is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check IIN's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
BDXA vs HRC Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, HRC has a market cap of 0. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas HRC's P/E ratio is 41.92. In terms of profitability, BDXA's ROE is +0.05%, compared to HRC's ROE of +0.14%. Regarding short-term risk, BDXA is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check HRC's competition here
Analogic Corporation (NASDAQ: ALOG)
BDXA vs ALOG Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, ALOG has a market cap of 0. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas ALOG's P/E ratio is 40.93. In terms of profitability, BDXA's ROE is +0.05%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, BDXA is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check ALOG's competition here